drugset / Trial / NCT05739630

M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia

NCT05739630

RandomizedParallel-groupOpen-labelTreatment

Summary

This study intends to evaluate the efficiency and safety of M-PTCy as conditioning regimen in Haploidentical HSCT for Acute Leukemia, so as to provide a new conditioning regimen for allogeneic hematopoietic cell transplantation.

Timeline

Start
2023-01-01
Primary completion
2024-01-31
Completion
2025-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator ATG Unknown 2.5 mg/kg
Subject Mitoxantrone Small molecule 36 mg/m2

Indications